Based on this assessment and the patient’s SLCO1B1 phenotype (reduced or poor function), the guidelines provide statin types/doses and their associated SAMS risk. This evidence concerns the gene SLCO1B1 and short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome.